Femasys Announces Second Quarter Financial Results for 2025
-- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio --
ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the second quarter of 2025.
Corporate Highlights from 2Q 2025 to date
Announced European Union Medical Device Regulation approval of FemBloc®, the first global regulatory endorsement of our groundbreaking non-surgical permanent birth control solution
Secured first European order for FemBloc from Spain distribution partners for approximately $400,000
Announced Australian and New Zealand regulatory approvals for FemaSeed® and FemVue®, a cost-effective first step in fertility
Announced new Chief Commercial Officer to help drive execution and global growth
Announced partnership with Carolinas Fertility Institute, one of America's best fertility clinics, to offer FemaSeed in its eight locations
Announced pricing of underwritten public offering and concurrent private placement with gross proceeds of $4.5 million
"Our second quarter marked several significant milestones for Femasys as we continue to secure key regulatory approvals, add partners, and strengthen our team to accelerate the commercialization of our innovative fertility portfolio across the globe," said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys. "European approval of the entire FemBloc System announced in June marks the first global regulatory endorsement of our groundbreaking non-surgical permanent birth control solution. FemBloc is commercially available through strategic distribution partnerships in select countries in Europe beginning in Spain, who placed their initial order, and we will seek additional country approvals while continuing to enroll participants in our FDA IDE-approved late-stage pivotal trial for U.S. approval.
"Regulatory approvals for FemaSeed in Australia and New Zealand announced in July also provide us with the opportunity to pursue meaningful commercial opportunities as we continue to grow revenue and broaden our global footprint. Our new partnership with Carolinas Fertility Institute will help us reach and support more patients earlier in their fertility journey. We look forward to building upon this momentum as we work towards transforming the fertility sector not only for patients, but also providers."
Financial Results for Quarter Ended June 30, 2025
Sales increased by $187,784, or 84.8%, to $409,268 for the three months of 2025, compared to $221,484 for the three months of 2024 due to sales of FemaSeed and FemVue.
Research and development expenses decreased by $561,446, or 28.4%, to $1,414,429 for the three months of 2025 compared to $1,975,875 for the three months of 2024 primarily due to commercialization of development products into inventory and reduced clinical costs, partially offset by increased compensation costs.
Net loss was $4,585,922, or ($0.16) per basic and diluted share attributable to common stockholders, for the three-month period ended June 30, 2025, compared to a net loss of $4,684,574, or ($0.21) per basic and diluted share attributable to common stockholders, for the three-month period ended June 30, 2024.
Cash and cash equivalents as of June 30, 2025, was approximately $3.2 million and the Company had an accumulated deficit of approximately $137.7 million. The Company expects, based on its current operating plan, our current cash and cash equivalents will be sufficient to fund its ongoing operations into early fourth quarter of 2025.
Financial Results for Six Months Ended June 30, 2025
Sales increased by $257,908, or 52.4%, to $750,532 for the six months of 2025, compared to $492,624 for the six months of 2024 due to sales of FemaSeed and FemVue.
Research and development expenses increased by $636,295, or 17.0%, to $4,382,901 for the six months of 2025 compared to $3,746,606 for the six months of 2024 primarily due to increased compensation and regulatory costs, partially offset by reduced material and development costs and clinical costs.
Net loss was $10,482,761, or ($0.39) per basic and diluted share attributable to common stockholders, for the six-month period ended June 30, 2025, compared to a net loss of $8,284,084, or ($0.38) per basic and diluted share attributable to common stockholders, for the same period ended June 30, 2024.
For more information, please refer to the Company's Form 10-Q filed August 8, 2025, which can be accessed on the SEC website.
FEMASYS INC.
Condensed Balance Sheets
(unaudited)
Assets
June 30,2025
December 31,2024
Current assets:
Cash and cash equivalents
$
3,218,067
3,451,761
Accounts receivable, net
254,584
488,373
Inventory
5,232,738
3,046,323
Prepaid and other current assets
1,045,591
1,035,993
Total current assets
9,750,980
8,022,450
Property and equipment, at cost:
Leasehold improvements
1,238,886
1,238,886
Office equipment
68,530
60,921
Furniture and fixtures
417,876
417,876
Machinery and equipment
3,211,109
2,856,740
Construction in progress
548,426
762,445
5,484,827
5,336,868
Less accumulated depreciation
(3,884,964
)
(3,740,769
)
Net property and equipment
1,599,863
1,596,099
Long-term assets:
Lease right-of-use assets, net
1,544,724
1,805,543
Intangible assets, net of accumulated amortization
55,638
65,918
Other long-term assets
829,204
954,992
Total long-term assets
2,429,566
2,826,453
Total assets
$
13,780,409
12,445,002
(continued)
FEMASYS INC.
Condensed Balance Sheets
(unaudited)
